D-0163-2025 Class II Terminated

Recalled by PD-Rx Pharmaceuticals, Inc. — Oklahoma City, OK

FDA drug recall D-0163-2025 was initiated by PD-Rx Pharmaceuticals, Inc. on Dec 4, 2024 and is designated Class II. Reason for recall: CGMP Deviations: the presence of a Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Duloxetine above the interim acceptable intake limit The recall status is terminated (terminated Mar 21, 2025). Affected quantity: 70, 90-count bottles.

Recall details

Product Type
Drugs
Report Date
Jan 1, 2025
Initiation Date
Dec 4, 2024
Termination Date
Mar 21, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
70, 90-count bottles

Product description

DULoxetine DR USP, 30 mg, 90-count bottle, Rx Only, Packaged by: PD Rx Pharmaceuticals Inc, Oklahoma City, OK 73127, NDC: 43063-877-90

Reason for recall

CGMP Deviations: the presence of a Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Duloxetine above the interim acceptable intake limit

Distribution pattern

Distributed within US: FL, MS, WI

Code information

Lot # I24E77, A24E49, Exp Date: 04/30/25; J23C50, J23C97, L23B39, L23E98, Exp Date: 01/31/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0163-2025
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0163-2025. Report a data issue: hello@regdatalab.com.